- Home
- NBHC vs AUPH Comparison
NBHC vs AUPH Comparison
Compare NBHC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBHC | AUPH |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2012 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NBHC | AUPH |
|---|---|---|
| Price | $37.95 | $15.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $44.33 | $17.25 |
| AVG Volume (30 Days) | 313.4K | ★ 1.0M |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.15 | 0.55 |
| Revenue | ★ $405,867,000.00 | $265,808,000.00 |
| Revenue This Year | $8.48 | $21.76 |
| Revenue Next Year | $28.10 | $16.45 |
| P/E Ratio | ★ $12.03 | $27.90 |
| Revenue Growth | 1.03 | ★ 20.62 |
| 52 Week Low | $32.83 | $6.55 |
| 52 Week High | $44.93 | $16.54 |
Technical Indicators
Market Signals| Indicator | NBHC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 44.46 |
| Support Level | $39.35 | $15.64 |
| Resistance Level | $40.68 | $15.98 |
| Average True Range (ATR) | 0.61 | 0.39 |
| MACD | -0.29 | -0.12 |
| Stochastic Oscillator | 8.36 | 20.26 |
Price Performance
Historical ComparisonAbout NBHC National Bank Holdings Corporation
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.